1. United States Stocks

  2. •

    Health technology

  3. •

    Biotechnology
Gilead Sciences, Inc.

Gilead Sciences, Inc.

155.50
USD
+2.00
(+1.30%)
-2.59EPS
156.37BMarket Cap
Oct 29Next Earn
Gilead Sciences, Inc.
IOB:0QYQ
(London Stock Exchange (International))

Recent

price

155.50

P/E

ratio

- -

div

yld

2.11%

ROIC.AI

2010
2011
2012
2013
2014
2015
2016
2017
2018
2019
2020
2021
2022
2023
2024
2025
TTM
USD
4.64
5.41
6.41
7.33
16.35
22.29
22.7
19.97
17.05
17.68
19.64
21.74
21.74
21.73
23.06
23.67
24.51
Revenue per Share
1.69
1.81
1.71
2.01
7.95
12.37
10.08
3.54
4.2
4.24
0.1
4.96
3.66
4.54
0.38
6.84
-2.61
Basic EPS, GAAP
1.66
2.35
2.11
2.03
8.42
14.52
12.73
9.1
6.47
7.2
6.5
9.06
7.23
5.95
8.26
7.6
10.42
Free Cash Flow per Basic Share
- -
- -
- -
- -
- -
1.28
1.83
2.09
2.29
2.54
2.74
2.87
2.96
3.05
3.14
3.22
3.27
Dividend per Share
3.66
4.47
6.12
7.41
10.29
13.03
14.42
15.63
16.68
17.79
14.52
16.8
17.03
18.32
15.51
18.3
9.53
Book Value per Share
2.77
3.1
-2.3
-1.11
2.12
5
6.67
-0.62
1.2
3.65
-18.37
-16.52
-12.8
-9.58
-7.17
-2.09
-8.48
Tangible Book Value per Share
1,712
1,550
1,515
1,529
1,522
1,464
1,339
1,307
1,298
1,270
1,257
1,256
1,255
1,248
1,247
1,244
1,243
Basic Weighted Avg Shares
7,949
8,385
9,702
11,202
24,890
32,639
30,390
26,107
22,127
22,449
24,689
27,305
27,281
27,116
28,754
29,442
30,456
Sales/Revenue/Turnover
49.84
45.2
41.33
40.39
61.33
68
58.02
54.1
42.02
41.6
40.21
39.76
40.23
32.59
36.85
39.74
38.47
Operating Margin (%)
265
302
278
345
1,050
1,098
1,158
1,286
1,429
1,404
1,480
2,050
2,103
2,693
2,767
2,760
2,760
Depreciation Expense
2,901
2,804
2,592
3,075
12,101
18,108
13,501
4,628
5,455
5,386
123
6,225
4,592
5,665
480
8,510
-3,240
Net Income, GAAP
26.16
23.61
28.74
27.35
18.83
16.4
21.11
65.67
29.99
- -
94.67
25.09
21.47
18.18
30.58
13.13
- -
Effective Tax Rate (%)
36.5
33.43
26.72
27.45
48.62
55.48
44.43
17.73
24.65
23.99
0.5
22.8
16.83
20.89
1.67
28.9
-10.64
Profit Margin (%)
3,243
11,404
1,918
590
11,953
14,872
10,370
20,188
25,231
20,537
4,599
3,162
3,205
4,805
7,169
6,529
2,925
Working Capital
2,839
7,606
7,055
3,939
11,921
21,073
26,346
30,795
24,574
22,094
28,645
25,179
22,957
23,189
24,896
22,129
23,832
LT Debt
6,122
6,867
9,544
11,745
15,819
19,113
19,363
20,501
21,534
22,650
18,221
21,064
21,209
22,749
19,246
22,618
11,744
Total Equity
33.67
24.36
17.96
18.43
53.74
54.43
32.6
9.75
11.17
- -
0.45
15.31
12.22
13.12
2.43
18.65
- -
Return on Invested Capital (%)
34.48
24.71
17.79
18.35
53.55
53.85
32.86
10.02
12.06
- -
0.43
14.37
11.36
13.78
2.47
20.1
- -
Return on Capital (%)
47.44
44.49
32.32
29.75
90.32
106.64
72.16
23.53
26.08
24.53
0.6
31.7
21.71
25.71
2.28
40.49
-20.57
Return on Common Equity (%)

Capital Structure

USD

•

in mil. unless spec.
Dec'25
Mar'26
Jun'26
ST Debt
2,807
1,313
2,414
LT Borrowings
22,129
20,861
23,832
LT Finance Leases
- -
- -
- -
Preferred Equity and Hybrid Capital
- -
- -
- -
Shares Outstanding
1,241
1,242
1,241
Market Capitalization
152,976
171,396
156,366

Working Capital

USD

•

in mil. unless spec.
Dec'25
Mar'26
Jun'26
Total Current Assets
18,342
18,641
13,945
Cash, Cash Equivalents & STI
9,613
7,643
3,179
Accounts Receivable, Net
4,913
4,741
5,055
Inventories
1,774
1,914
1,953
Total Current Liabilities
11,813
9,475
11,020
Payables & Accruals
5,144
4,763
4,907
ST Debt
2,807
1,313
2,414
Deferred Revenue
- -
- -
- -

Growth Rates

USD

•

in mil. unless spec.

(avg. rate of change)

10 years
5 years
1 year
Total Equity
2.35%
5.13%
17.52%
Free Cash Flow
-4.97%
6.3%
-8.24%
Net Income, GAAP
636.72%
1,307.9%
1,672.92%
Sales/Revenue/Turnover
-0.64%
3.67%
2.39%
Total Cash Common Dividend
8.17%
3.03%
2.17%

Quarterly Revenue

USD

•

in mil. unless spec.

Year

Q1
Q2
Q3
Q4
FY
2024
6,686
6,953
7,545
7,569
28,754
2025
6,667
7,081
7,769
7,924
29,442
2026
6,960
7,803
- -
- -
- -

Quarterly Earnings Per Share

USD

•

in mil. unless spec.

Year

Q1
Q2
Q3
Q4
FY
2024
-3.34
1.29
1
1.43
0.38
2025
1.06
1.57
2.46
1.76
6.84
2026
1.63
-8.44
- -
- -
- -

Quarterly Dividends Per Share

USD

•

in mil. unless spec.

Year

Q1
Q2
Q3
Q4
FY
2024
0.79
0.78
0.79
0.78
3.14
2025
0.81
0.8
0.81
0.8
3.22
2026
0.84
0.83
- -
- -
- -
Similar Companies
Moderna, Inc. (NASDAQ:MRNA)
Amgen Inc. (NASDAQ:AMGN)
Iovance Biotherapeutics, Inc. (NASDAQ:IOVA)
Recursion Pharmaceuticals, Inc. (NASDAQ:RXRX)
Novavax, Inc. (NASDAQ:NVAX)
10x Genomics, Inc. (NASDAQ:TXG)
Business
Gilead Sciences, Inc. (Nasdaq: GILD) is a research-based biopharmaceutical company that discovers, develops and commercializes innovative medicines in areas of unmet medical need, with primary focus areas including HIV/AIDS, viral hepatitis, oncology, inflammation and serious respiratory diseases. The company markets a portfolio of marketed products such as Biktarvy, Descovy, Truvada and Veklury for virology; Epclusa, Vosevi and Vemlidy for liver diseases; Trodelvy, Tecartus and Yescarta for oncology; and investigational assets across its therapeutic areas, including complete regimen single-tablet treatments for HIV, nucleotide reverse transcriptase inhibitors and NS5A/NS5B inhibitors for hepatitis C. Founded in 1987 and headquartered in Foster City, California, Gilead operates globally with facilities across North America, Europe (including international headquarters in Stockley Park, UK), Asia-Pacific (such as Japan, China and Australia) and approximately 17,000 employees worldwide. Recent strategic developments include a $32 billion U.S. investment commitment by 2030 to expand manufacturing and R&D capabilities, highlighted by the September 2025 groundbreaking of a new Pharmaceutical Development and Manufacturing Technical Development Center in Foster City projected to create thousands of jobs; an up-to-$400 million acquisition in November 2025 of Sprint Bioscience's preclinical TREX1 oncology immunotherapy program; a $350 million buyout in August 2025 of Interius BioTherapeutics by subsidiary Kite Pharma to advance in vivo CAR-T cell therapies for cancer; a January 2025 strategic partnership with LEO Pharma acquiring rights to preclinical oral STAT6 inhibitors and targeted protein degraders for inflammatory diseases; and an expanded agreement with Cognizant in early 2025 to enhance productivity through advanced technologies.

Company News

Company News APIChatGPT

  • businesswire.com

    Gilead to Present New Data on Treatment Response and Long-Term Management of Rare Liver Diseases at The Liver Meeting® 2026

  • reuters.com

    BioNTech, Gilead to test drug combination in advanced breast cancer trial

  • fool.com

    Biotech Giants vs. Emerging Innovators: Which ETF Is the Better Buy?

  • zacks.com

    Gilead Sciences (GILD) Stock Drops Despite Market Gains: Important Facts to Note

  • defenseworld.net

    15,240 Gilead Sciences, Inc. $GILD Shares Bought by CWA Asset Management Group LLC

  • zacks.com

    All You Need to Know About Gilead (GILD) Rating Upgrade to Buy

  • businesswire.com

    Gilead to Present New Data Across HIV and Emerging Antiviral Research at IDWeek 2026

  • reuters.com

    Gilead's pill succeeds in mid-stage bowel disease trial

  • defenseworld.net

    Insider Selling: Gilead Sciences (NASDAQ:GILD) Insider Sells $468,660.00 in Stock

  • defenseworld.net

    Insider Selling: Gilead Sciences (NASDAQ:GILD) CFO Sells $468,660.00 in Stock

  • fool.com

    Gilead Sciences Is on an FDA Approval Hot Streak. Should You Buy the Stock Like There's No Tomorrow?

  • zacks.com

    Gilead Sciences (GILD) Rises Higher Than Market: Key Facts

  • zacks.com

    Can Gilead's Deal With VIR Boost Its Oncology Pipeline and Growth?

  • youtube.com

    The Big 3: MRK, GILD, XOM

  • zacks.com

    Gilead Sciences, Inc. (GILD) is Attracting Investor Attention: Here is What You Should Know

  • benzinga.com

    Vir Biotechnology, Gilead Strike Deal for Novel Tumor Treatments

  • 247wallst.com

    Blockbuster Drugs Come and Go. These 5 Pharma Dividend Stocks Keep Paying

  • defenseworld.net

    Gilead Sciences, Inc. $GILD Stock Acquired by RHS Financial LLC

  • fool.com

    Which Pharmaceuticals ETF Is the Better Buy: iShares’ IHE or Invesco’s PJP?

  • defenseworld.net

    Head to Head Contrast: Gilead Sciences (NASDAQ:GILD) vs. GRAIL (NASDAQ:GRAL)